-
Waiting for the “liquid revolution” in the adjuvant treatment of colon cancer patients: a review of ongoing trials Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-04-04 V. Conca, P. Ciracì, C. Boccaccio, A. Minelli, C. Antoniotti, C. Cremolini
Since colon cancer has a high rate of shedding of tumour fragments into the blood, several research efforts are now focused on the investigation of the minimal residual disease through the detection of ctDNA to tailor the adjuvant therapy of colon cancer patients and optimize its cost/effectiveness balance. The negative prognostic impact of detectable ctDNA in patients’ blood after radical surgery
-
Endocrine-metabolic assessment checklist for cancer patients treated with immunotherapy: A proposal by the Italian Association of Medical Oncology (AIOM), Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology (SIE) and Italian Society of Pharmacology (SIF) multidisciplinary group Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-04-03 Maria Chiara Zatelli, Antongiulio Faggiano MD, Antonella Argentiero, Romano Danesi, Stella D'Oronzo, Stefano Fogli, Tindara Franchina, Francesco Giorgino, Nicola Marrano, Dario Giuffrida, Stefania Gori, Giampiero Marino, Rossella Mazzilli, Matteo Monami, Monica Montagnani, Lelio Morviducci, Annalisa Natalicchio, Alberto Ragni, Valerio Renzelli, Antonio Russo, Laura Sciacca, Enzo Tuveri, Gianluca Aimaretti
Immunotherapy with immune checkpoint inhibitors (ICI) is increasingly employed in oncology. National and international endocrine and oncologic scientific societies have provided guidelines for the management of endocrine immune-related adverse events. However, guidelines recommendations differ according to the specific filed, particularly pertaining to recommendations for the timing of endocrine testing
-
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-30 Elena Palassini, Giacomo Giulio Baldi, Sara Sulfaro, Marta Barisella, Giuseppe Bianchi, Domenico Campanacci, Marco Fiore, Marco Gambarotti, Massimiliano Gennaro, Carlo Morosi, Federico Navarria, Emanuela Palmerini, Claudia Sangalli, Marta Sbaraglia, Annalisa Trama, Sebastian Asaftei, Giuseppe Badalamenti, Rossella Bertulli, Alexia Francesca Bertuzzi, Roberto Biagini, Angela Bonadonna, Antonella Brunello
Angiosarcoma (AS) represents a rare and aggressive vascular sarcoma, posing distinct challenges in clinical management compared to other sarcomas.
-
First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-29 Rana R. McKay, Alicia K. Morgans, Neal D. Shore, Curtis Dunshee, Geeta Devgan, Neeraj Agarwal
Metastatic castration-resistant prostate cancer (mCRPC) remains incurable and develops from biochemically recurrent PC treated with androgen deprivation therapy (ADT) following definitive therapy for localized PC, or from metastatic castration-sensitive PC (mCSPC). In the mCSPC setting, treatment intensification of ADT plus androgen receptor (AR)–signaling inhibitors (ARSIs), with or without chemotherapy
-
Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-28 Robert Li Sucholeiki, Casey L. Propst, David S. Hong, Goldy C. George
Intermittent fasting is a dietary intervention that is increasingly being tested for positive outcomes in patients receiving cancer treatment. In this review, we examine the impact of intermittent fasting on symptoms, toxicities, and quality of life in patients undergoing cancer therapy and highlight unmet investigative areas to prompt future research. While current evidence is preliminary and conclusions
-
Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-27 Christopher Grant, Misako Nagasaka
Non-small cell lung cancer (NSCLC) stages I-III are predominantly treated with surgery and combination immunotherapy and chemotherapy. A majority of these studies excluded patients with and alterations. There are several completed and ongoing trials evaluating neoadjuvant treatment with monotherapy, combination therapy with chemotherapy, and combination therapy with immunotherapy. Here, we review completed
-
Molecular characterization as new driver in prognostic signatures and therapeutic strategies for endometrial cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-27 Elisa D'Agostino, Luciana Mastrodomenico, Ornella Ponzoni, Cinzia Baldessari, Claudia Piombino, Stefania Pipitone, Maria Giuseppa Vitale, Roberto Sabbatini, Massimo Dominici, Angela Toss
-
If it’s a target, it’s a pan-cancer target: Tissue is not the issue Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-21 Jacob J. Adashek, Shumei Kato, Jason K. Sicklick, Scott M. Lippman, Razelle Kurzrock
-
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672] Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-16 Arianna Dri, Grazia Arpino, Giampaolo Bianchini, Giuseppe Curigliano, Romano Danesi, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Alessandra Gennari, Valentina Guarneri, Daniele Santini, Edda Simoncini, Claudio Zamagni, Fabio Puglisi
-
The more the merrier? Evidence and efficacy of immune checkpoint- and tyrosine kinase inhibitor combinations in advanced solid cancers Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-15 Angelika M. Starzer, Ladislaia Wolff, Petar Popov, Barbara Kiesewetter, Matthias Preusser, Anna S. Berghoff
-
Bridging gaps in cancer cachexia Care: Current insights and future perspectives Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-13 Carlotta Bianchini, Pierluigi Bonomo, Paolo Bossi, Riccardo Caccialanza, Alessandra Fabi
Cachexia is characterized by severe weight loss and skeletal muscle depletion, and is a threat to cancer patients by worsening their prognosis. International guidelines set indications for the screening and diagnosis of cancer cachexia and suggest interventions (nutritional support, physical exercise, and pharmacological treatments). Nevertheless, real-life experience not always aligns with such indications
-
Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-12 Elena Brozos-Vázquez, Marta Toledano-Fonseca, Nicolás Costa-Fraga, María Victoria García-Ortiz, Ángel Díaz-Lagares, Antonio Rodríguez-Ariza, Enrique Aranda, Rafael López-López
Pancreatic cancer is one of the tumors with the worst prognosis, and unlike other cancers, few advances have been made in recent years. The only curative option is surgery, but only 15–20% of patients are candidates, with a high risk of relapse. In advanced pancreatic cancer there are few first-line treatment options and no validated biomarkers for better treatment selection. The development of targeted
-
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-11 Rebecca S. Heist, Jacob Sands, Aditya Bardia, Toshio Shimizu, Aaron Lisberg, Ian Krop, Noboru Yamamoto, Takahiro Kogawa, Saba Al-Hashimi, Simon S.M. Fung, Anat Galor, Francesca Pisetzky, Priyanka Basak, Cindy Lau, Funda Meric-Bernstam
Antibody drug conjugates (ADCs) are an emerging class of treatments designed to improve efficacy and decrease toxicity compared with other systemic therapies through the selective delivery of cytotoxic agents to tumor cells. Datopotamab deruxtecan (Dato-DXd) is a novel ADC comprising a topoisomerase I inhibitor payload and a monoclonal antibody directed to trophoblast cell-surface antigen 2 (TROP2)
-
Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-11 A. Kyriazoglou, A. Pagkali, I. Kotsantis, P. Economopoulou, M. Kyrkasiadou, M. Moutafi, N. Gavrielatou, M. Anastasiou, A. Boulouta, A. Pantazopoulos, M. Giannakakou, A. Digklia, A. Psyrri
Well-differentiated liposarcomas (WDLPS) and dedifferentiated liposarcomas (DDLPS) account for 60 % of all liposarcomas, reflecting the heterogeneity of this type of sarcoma. Genetically, both types of liposarcomas are characterized by the amplification of and genes, which indicates an important molecular event with diagnostic and therapeutic relevance. In both localized WDLPS and DDLPS of the retroperitoneum
-
How to manage waldenström’s macroglobulinemia in 2024 Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-05 Alexander Grunenberg, Christian Buske
Clinical management of Waldenström’s Macroglobulinemia has seen major progress in the recent years, triggered by our improved understanding of the biology of the disease and the development of new therapies. Based on this there are multiple treatment options available for patients with WM ranging from classical immunochemotherapy to targeted approaches blocking key enzymes involved in lymphoma growth
-
Tumor-agnostic baskets to N-of-1 platform trials and real-world data: Transforming precision oncology clinical trial design Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-04 Elena Fountzilas, Apostolia-Maria Tsimberidou, Henry Hiep Vo, Razelle Kurzrock
Choosing the right drug(s) for the right patient via advanced genomic sequencing and multi-omic interrogation is the of precision cancer medicine. Traditional cancer clinical trial designs follow well-defined protocols to evaluate the efficacy of new therapies in patient groups, usually identified by their histology/tissue of origin of their malignancy. In contrast, precision medicine seeks to optimize
-
Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-03-01 K.R.J. Kistemaker, F. Sijani, D.J. Brinkman, A. de Graeff, G.L. Burchell, M.A.H. Steegers, L. van Zuylen
Cancer-related pain often requires opioid treatment with opioid-induced constipation (OIC) as its most frequent gastrointestinal side-effect. Both for prevention and treatment of OIC osmotic (e.g. polyethylene glycol) and stimulant (e.g. bisacodyl) laxatives are widely used. Newer drugs such as the peripherally acting µ-opioid receptor antagonists (PAMORAs) and naloxone in a fixed combination with
-
Cancer genetic counselling for hereditary breast cancer in the era of precision oncology Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-28 M. Pensabene, A. Calabrese, C. von Arx, R. Caputo, M. De Laurentiis
-
Incorporation of anti-PD1 or anti PD-L1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-27 Michele Bartoletti, Marcella Montico, Domenica Lorusso, Roberta Mazzeo, Ana Oaknin, Lucia Musacchio, Giovanni Scambia, Fabio Puglisi, Sandro Pignata
Various randomized trials have explored the efficacy of combining immune checkpoint inhibitors (ICIs) with first-line chemotherapy in advanced endometrial cancer. We aimed to summarize available data and clarify the benefit of adding immunotherapy according to the DNA mismatch repair status (deficient, dMMR or proficient, pMMR) and the specific type of agent used (anti-PD1 or anti-PD-L1). To assess
-
Current advances in targeted therapy for metastatic colorectal cancer – Clinical translation and future directions Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-24 David Johnson, Cheng Ean Chee, Wesley Wong, Rachel C.T. Lam, Iain Bee Huat Tan, Brigette B.Y. Ma
The last two decades have witnessed major breakthroughs in the development of targeted therapy for patients with metastatic colorectal cancer (mCRC), an achievement which stems largely from advances in translational research. Precision medicine is now widely practiced in routine oncological care, where systemic therapy is individualized based on clinical factors such as primary tumor sidedness, location
-
177Lu-PSMA therapy in metastatic prostate cancer: An updated review of prognostic and predictive biomarkers Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-17 Emilio Francesco Giunta, Nicole Brighi, Giorgia Gurioli, Federica Matteucci, Giovanni Paganelli, Ugo De Giorgi
177Lu-PSMA has been approved for the treatment of PSMA-positive metastatic castration-resistant (mCRPC) patients who progressed to androgen receptor pathway inhibitors (ARPIs) and taxane-based chemotherapy. However, a higher proportion of patients do not respond to this type of radioligand therapy (RLT). To date, there is a lack of validated prognostic and predictive biomarkers for 177Lu-PSMA therapy
-
Salivary gland carcinoma: Towards a more personalised approach Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-12 Layal Rached, Khalil Saleh, Odile Casiraghi, Caroline Even
Salivary Gland carcinomas (SGCs) are rare tumors accounting for less than 1% of all cancers with 21 histologically diverse subtypes. The rarity of the disease presents a challenge for clinicians to conduct large size randomized controlled trials. Surgery and radiotherapy remain the only curative treatment for localized disease, whereas treatments for recurrent and metastatic disease remain more challenging
-
Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-11 Matteo Bauckneht, Chiara Ciccarese, Riccardo Laudicella, Claudia Mosillo, Francesca D'Amico, Annunziato Anghelone, Alessandro Strusi, Viria Beccia, Sergio Bracarda, Giuseppe Fornarini, Giampaolo Tortora, Roberto Iacovelli
In the last years, theranostics has expanded the therapeutic options available for prostate cancer patients. In this review, we explore this dynamic field and its potential to revolutionize precision medicine for prostate cancer. We delve into the foundational principles, clinical applications, and emerging opportunities, emphasizing the potential synergy between radioligand therapy and other systemic
-
Preoperative chemotherapy in upfront resectable colorectal liver metastases: New elements for an old dilemma? Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-07 Lorenzo Bernardi, Raffaello Roesel, Davit L. Aghayan, Pietro E. Majno-Hurst, Sara De Dosso, Alessandra Cristaudi
The use of preoperative or “neoadjuvant” chemotherapy (NAC) has long been controversial for resectable colorectal liver metastases (CRLM). The European Society of Medical Oncology (ESMO) 2023 guidelines on metastatic colorectal cancer (CRC) indicate a combination of surgical/technical and oncologic/prognostic criteria as the two determinants for allocating patients to NAC or upfront hepatectomy. However
-
High-dose chemotherapy for Ewing sarcoma and Rhabdomyosarcoma: A systematic review by the Australia and New Zealand sarcoma association clinical practice guidelines working party Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-02 Ashika Ramamurthy, Elizabeth A Connolly, Jasmine Mar, Jeremy Lewin, Vivek A Bhadri, Marianne B Phillips, Mark Winstanley, Lisa M Orme, Peter Grimison, Joanna Connor, Smaro Lazarakis, Angela M Hong, Natacha Omer, Julie Cayrol
Patients with high-risk or metastatic Ewing sarcoma (ES) and rhabdomyosarcoma (RMS) have a guarded prognosis. High-dose chemotherapy (HDT) with autologous stem cell transplant (ASCT) has been evaluated as a treatment option to improve outcomes. However, survival benefits remain unclear, and treatment is associated with severe toxicities. A systematic review was conducted, using the population, intervention
-
Challenges to genetic testing for germline mutations associated with breast cancer among African Americans Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-02-01 S. Kamaraju, M. Conroy, A. Harris, M. Georgen, H. Min, M. Powell, R. Kurzrock
-
A conceptual framework for cautious escalation of anticancer treatment: How to optimize overall benefit and obviate the need for de-escalation trials Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-01-30 I. Pourmir, H.K. Van Halteren, R. Elaidi, D. Trapani, F. Strasser, G. Vreugdenhil, M. Clarke
The developmental workflow of the currently performed phase 1, 2 and 3 cancer trial stages lacks essential information required for the determination of the optimal efficacy threshold of new anticancer regimens. Due to this there is a serious risk of overdosing and/or treating for an unnecessary long time, leading to excess toxicity and a higher financial burden for society. But often post-approval
-
How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for Oncologists Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-01-23 Tucci Marcello, Cosmai Laura, Pirovano Marta, Campisi Ilaria, Re Sartò Giulia Vanessa, Porta Camillo, Gallieni Maurizio, Piergiorgio Messa
-
-
Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-01-17 Javier Munoz, Anagha Deshpande, Lisa Rimsza, Grzegorz S. Nowakowski, Razelle Kurzrock
In treating diffuse large B-cell lymphoma (DLBCL), oncologists have traditionally relied on the chemotherapy backbone of R-CHOP as standard of care. The two dangers that the hematologist must navigate between are the aggressive disease (Charybdis that in the absence of therapy systematically destroys all the ships) and the toxicity of the therapies (Scylla with its six monstrous heads that devours
-
Optimizing lung cancer radiation therapy: A systematic review of multifactorial risk assessment for radiation-induced lung toxicity Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-01-13 Rayan Bensenane, Sylvie Helfre, Kim Cao, Matthieu Carton, Laurence Champion, Nicolas Girard, Matthieu Glorion, Thibaut Vieira, Waisse Waissi, Gilles Crehange, Arnaud Beddok
Radiation therapy (RT) is essential in treating advanced lung cancer, but may lead to radiation pneumonitis (RP). This systematic review investigates the use of pulmonary function tests (PFT) and other parameters to predict and mitigate RP, thereby improving RT planning. A systematic review sifted through PubMed and on BioMed Central, targeting articles from September 2005 to December 2022 containing
-
The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review Cancer Treat. Rev. (IF 11.8) Pub Date : 2024-01-12 Davide Ciardiello, Gianluca Mauri, Andrea Sartore-Bianchi, Salvatore Siena, Maria Giulia Zampino, Nicola Fazio, Andres Cervantes
Despite recent molecular and immunological advancements, prognosis of metastatic colorectal cancer (mCRC) patients remains poor. In this context, several retrospective and phase II studies suggested that after failure of an upfront anti-EGFR based regimen, a subset of patients can still benefit from further anti-EGFR blockade.
-
Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-25 Rebecca Ibrahim, Tarek Assi, Rita Khoury, Carine Ngo, Matthieu Faron, Benjamin Verret, Antonin Lévy, Charles Honoré, Clémence Hénon, Cécile Le Péchoux, Ratislav Bahleda, Axel Le Cesne
Desmoid tumors (DT) are rare, slow-growing, locally invasive soft tissue tumors that often pose significant therapeutic challenges. Traditional management strategies including active surveillance, surgery, radiotherapy, and systemic therapy which are associated with varying recurrence rates and high morbidity. Given the challenging nature of DT and the modest outcomes associated with current treatment
-
Histology independent drug development – Is this the future for cancer drugs? Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-23 Lucinda Billingham, Lynn Brown, Theodor Framke, Alastair Greystoke, Eivind Hovig, Siddhartha Mathur, Philippe Page, Elias Pean, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Richardus Vonk, Sacha Wissink, Hilke Zander, Ruth Plummer
The Cancer Drug Development Forum (CDDF)’s ‘Histology independent drug development – is this the future for cancer drugs?’ workshop was set up to explore the current landscape of histology independent drug development, review the current regulatory landscape and propose recommendations for improving the conduct of future trials. The first session considered lessons learnt from previous trials, including
-
Neoadjuvant chemotherapy for early-stage colon cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-23 Alessandro Audisio, Roberta Fazio, Valentina Daprà, Irene Assaf, Alain Hendlisz, Francesco Sclafani
Surgery with or without adjuvant chemotherapy is the standard treatment for early-stage colon cancer. However, evidence has recently emerged for neoadjuvant chemotherapy, with the results of randomised clinical trials sparking debates within multidisciplinary teams and splitting the gastrointestinal oncology community. Further to a systematic search of the literature, we provide a thorough and in-depth
-
The state of the art of EGFR exon 20 insertions in non-small cell lung cancer: Diagnosis and future perspectives Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-20 Miriam Dorta-Suárez, Maria de Miguel, Oscar Amor-Carro, José Miguel Calderón, MCarmen González-Ortega, Delvys Rodríguez-Abreu
Insertions in the epidermal growth factor receptor (EGFR) exon 20 (Ex20Ins) are the third most incident mutations in non-small cell lung cancer (NSCLC). The hypervariable nature of these driver mutations hinders their identification by traditional polymerase chain reaction (PCR)-based methods, requiring a comprehensive sequencing approach to detect all possible insertions. The prognosis of patients
-
Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-19 Almuth Maria Anni Merz, Marie Sébert, Jan Sonntag, Anne Sophie Kubasch, Uwe Platzbecker, Lionel Adès
Recent developments in high-risk Myelodysplastic Neoplasms (HR MDS) treatment are confronted with challenges in study design due to evolving drug combinations with Hypomethylating Agents (HMAs). The shift from the International Prognostic Scoring System (IPSS) to its molecular revision (IPSS-M) has notably influenced research and clinical practice. Introducing concepts like the MDS/AML overlap complicate
-
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs) Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-14 Arianna Dri, Grazia Arpino, Giampaolo Bianchini, Giuseppe Curigliano, Romano Danesi, Michelino De Laurentiis, Lucia Del Mastro, Alessandra Fabi, Daniele Generali, Alessandra Gennari, Valentina Guarneri, Daniele Santini, Edda Simoncini, Claudio Zamagni, Fabio Puglisi
Antibody-drug conjugates (ADCs) represent a novel class of molecules composed of a recombinant monoclonal antibody targeted to a specific cell surface antigen, conjugated to a cytotoxic agent through a cleavable or non-cleavable synthetic linker. The rationale behind the development of ADCs is to overcome the limitations of conventional chemotherapy, such as the narrow therapeutic window and the emergence
-
MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-10 Neeta Somaiah, William Tap
Well-differentiated and dedifferentiated liposarcomas (WDLPS and DDLPS) are rare tumors that arise from lipocytes in soft tissue. There is a high unmet need in patients with these liposarcomas given poor outcomes, particularly for DDLPS. WDLPS and DDLPS share important genetic and histological characteristics – most notably, the amplification of the 2 genes MDM2 and CDK4. Both genes are considered
-
Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-10 Hatice Bolek, Emre Yekedüz, Yüksel Ürün
Introduction Immunotherapy (IO)-based combination therapies have emerged as the standard of care for first-line treatment of metastatic renal cell carcinoma (mRCC) among patients classified as intermediate and poor risk. However, in the favorable risk group, the available data remains less compelling. This study aims to assess and compare the effectiveness of IO-based combination therapies versus tyrosine
-
Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-10 Luca Cantini, Dario Trapani, Lorenzo Guidi, Luca Boscolo Bielo, Roberta Scafetta, Marcin Koziej, Laura Vidal, Kamal S. Saini, Giuseppe Curigliano
Neoadjuvant therapy is commonly used in patients with locally advanced or inoperable breast cancer (BC). Neoadjuvant chemotherapy (NACT) represents an established treatment modality able to downstage tumours, facilitate breast-conserving surgery, yet also achieve considerable pathologic complete response (pCR) rates in HER2-positive and triple-negative BC. For patients with HR+/HER2- BC, the choice
-
Current and emerging treatment approaches for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-09 Komal Jhaveri, Frederik Marmé
In the past decade, significant progress was made in treating hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer (mBC), but many clinical questions remain. Cyclin-dependent kinase 4/6 inhibitors are now widely used in combination with endocrine therapy (ET) as standard of care, having demonstrated significant progression-free survival
-
Reporting of post-protocol therapies in metastatic breast cancer registration clinical trials: A systematic review Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-12-01 Shlomit Strulov Shachar, Yasmin Korzets, Daniel Shepshelovich, Noa Zlothover, Eitan Amir, Ariadna Tibau, Hadar Goldvaser
Background As the treatment for metastatic breast cancer (MBC) often includes sequential lines of therapy, data on post-protocol treatment in clinical trials are valuable in the assessment of long-term outcomes. The objective of this study was to assess the reported data on post-protocol therapy in clinical trials supporting US Food and Drug Administration (FDA) approval of drugs for MBC. Methods All
-
Review – The impact of pharmacogenetics on the outcome of immune checkpoint inhibitors Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-27 Karlijn de Joode, Niels Heersche, Edwin A. Basak, Sander Bins, Astrid A.M. van der Veldt, Ron H.N. van Schaik, Ron H.J. Mathijssen
-
Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-27 Celine Man Ying Li, Runhao Li, Paul Drew, Timothy Price, Eric Smith, Guy J. Maddern, Yoko Tomita, Kevin Fenix
Colorectal cancer (CRC) remains a significant global health burden and is the second leading cause of cancer-related death. Cytokine induced killer (CIK) cell therapy is an immunotherapy which has the potential to meet this need. Clinical trials of CIK cell therapy for the management of CRC have reported improved clinical outcomes. However, production and delivery protocols varied significantly, and
-
A systematic review of the role of chemotherapy in retroperitoneal sarcoma by the Australia and New Zealand sarcoma association clinical practice guidelines working party Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-25 Deborah Di-Xin Zhou, Elizabeth A Connolly, Jasmine Mar, Smaro Lazarakis, Peter S Grimison, Joanna Connor, David E Gyorki, Angela M Hong
Background In primary localised resectable retroperitoneal sarcoma (RPS), loco-regional and distant relapse occur frequently despite optimal surgical management. The role of chemotherapy in improving outcomes is unclear. Methods A systematic review was conducted, using the population, intervention, comparison outcome (PICO) model, to evaluate whether neoadjuvant or adjuvant chemotherapy improve outcomes
-
The role of anti-EGFR therapies in EGFR-TKI-resistant advanced non-small cell lung cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-25 Fortunato Ciardiello, Fred R. Hirsch, Robert Pirker, Enriqueta Felip, Christian Valencia, Egbert F. Smit
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are the current recommended option for the first-line treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC). Resistance to first-generation TKIs led to the development of second- and third-generation TKIs with improved clinical outcomes. However, sequential administration of TKIs has led to the emergence of
-
-
Pharmacotherapy for leptomeningeal disease in breast cancer Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-07 Rupert Bartsch, Katarzyna J. Jerzak, Louis Larrouquere, Volkmar Müller, Emilie Le Rhun
Clinical data supporting the best therapeutic approach in leptomeningeal disease (LMD; also known as leptomeningeal metastases or leptomeningeal carcinomatosis) are lacking. Despite the development of new agents and increasing incidence of central nervous system metastases, patients with LMD are often excluded from clinical trials in breast cancer, with very few conducted specifically in LMD. Consequently
-
Vascular endothelial growth factor-targeted therapy in patients with renal cell carcinoma pretreated with immune checkpoint inhibitors: A systematic literature review Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-04 Laurence Albiges, Bradley A. McGregor, Daniel Y.C. Heng, Giuseppe Procopio, Guillermo de Velasco, Naila Taguieva-Pioger, Lidia Martín-Couce, Nizar M. Tannir, Thomas Powles
Introduction We conducted a systematic literature review to identify evidence for use of vascular endothelial growth factor (VEGF)-targeted (anti-VEGF) treatment in patients with renal cell carcinoma (RCC) following prior checkpoint inhibitor (CPI)-based therapy. Methods This was a PRISMA-standard systematic literature review; registered with PROSPERO (CRD42021255568). Literature searches were conducted
-
Recent advances in genomics and therapeutics in mantle cell lymphoma Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-11-04 Tingxun Lu, Jie Zhang, Jenna M. McCracken, Ken H. Young
Over the past decades, significant strides have been made in understanding the pathobiology, prognosis, and treatment options for mantle cell lymphoma (MCL). The heterogeneity observed in MCL's biology, genomics, and clinical manifestations, including indolent and aggressive forms, is intricately linked to factors such as the mutational status of the variable region of the immunoglobulin heavy chain
-
Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-31 Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, Angela Lamarca, Paul Hofman, Luigi Terracciano, Nicola Normanno
-
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-31 Lorena Incorvaia, Alessandro Perez, Claudia Marchetti, Chiara Brando, Valerio Gristina, Daniela Cancelliere, Alessia Pivetti, Silvia Contino, Emilia Di Giovanni, Nadia Barraco, Marco Bono, Ambra Giurintano, Tancredi Didier Bazan Russo, Andrea Gottardo, Sofia Cutaia, Erika Pedone, Marta Peri, Lidia Rita Corsini, Daniele Fanale, Antonio Galvano, Viviana Bazan
-
Antibody based therapies in Hodgkin lymphoma Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-28 Vivek S. Radhakrishnan, Jemma Longley, Peter W.M. Johnson
Multimodality treatment approaches, with systemic therapies at their core, have made Hodgkin Lymphoma a highly curable cancer. Unmet needs remain. Resistance to therapy manifested by refractory and relapsed disease, and treatment related short- and long-term morbidity are the key challenges. Patient outcomes have improved in the recent past with the advent of novel therapies and are borne out of a
-
Sex dimorphism and cancer immunotherapy: May pregnancy solve the puzzle? Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-26 Francesco Maria Venanzi, Marta Bini, Antonio Nuccio, Alessandro De Toma, Matteo Lambertini, Francesca Rita Ogliari, Sara Oresti, Maria Grazia Viganò, Elena Brioschi, Maggie Polignano, Matteo Maria Naldini, Silvia Riva, Michele Ferrara, Nicola Fogale, Giuseppe Damiano, Vincenzo Russo, Michele Reni, Giulia Veronesi, Giorgia Foggetti, Fabio Conforti, Roberto Ferrara
In the immunoncology era, growing evidence has shown a clear sex dimorphism in antitumor immune response with a potential impact on outcomes upon immunecheckpoint blockade (ICI) in patients with cancer. Sex dimorphism could affect tumor microenvironment composition and systemic anticancer immunity; however, the modifications induced by sex are heterogeneous. From a clinical perspective, six metanalyses
-
Malignant ascites: Current therapy options and treatment prospects Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-24 Julia M. Berger, Matthias Preusser, Anna S. Berghoff, Elisabeth S. Bergen
Ascites formation is a common complication of cancer with a significant symptomatic burden for patients. Malignant ascites (MA) is defined by the presence of tumor cells within the ascitic fluid. It does not only cause substantial morbidity, but is also associated with impaired survival. Considering the frequent occurrence of MA, it still represents a clinical challenge for physicians with limited
-
Favorable impact of therapy management by an interactive eHealth system on severe adverse events in patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer treated by palbociclib and endocrine therapy Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-18 Nadia Harbeck, Ronald Kates, Timo Schinköthe, Johannes Schumacher, Rachel Wuerstlein, Tom Degenhardt, Diana Lüftner, Philip Räth, Oliver Hoffmann, Ralf Lorenz, Thomas Decker, Mattea Reinisch, Thomas Göhler, Peter Staib, Oleg Gluz, Peter A Fasching, Marcus Schmidt
Background Oral cancer medications offer advantages but also pose challenges for therapy management and adherence. An eHealth-based platform such as CANKADO can help to support therapy management by probing the patient’s quality of life (QoL) continuously throughout the course of treatment. Material and Methods AGO-B WSG PreCycle (NCT03220178) is a multicenter, randomized phase IV intergroup trial
-
Evolution of the HIF targeted therapy in clear cell renal cell carcinoma Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-15 Borivoj Golijanin, Kamil Malshy, Sari Khaleel, Galina Lagos, Ali Amin, Liang Cheng, Dragan Golijanin, Anthony Mega
Clear cell renal cell carcinoma (ccRCC) is the most common type of kidney cancer, affecting hundreds of thousands of people worldwide and can affect people of any age. The pathogenesis of ccRCC is most commonly due to biallelic loss of the tumor suppressor gene VHL. VHL is the recognition subunit of an E3-ubiquitin-ligase-complex essential for degradation of the hypoxia-inducible factors (HIF) 1α and
-
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-13 Konstantinos Venetis, Francesco Pepe, Carlo Pescia, Giulia Cursano, Carmen Criscitiello, Chiara Frascarelli, Eltjona Mane, Gianluca Russo, Beatrice Taurelli Salimbeni, Giancarlo Troncone, Elena Guerini Rocco, Giuseppe Curigliano, Nicola Fusco, Umberto Malapelle
Activating mutations of the estrogen receptor alpha gene (ESR1) are common mechanisms of endocrine therapy (ET) resistance in hormone receptor-positive (HR + )/Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic breast cancer (MBC). Recent clinical findings emphasize that both old and new generations of selective ER degraders (SERDs) demonstrate enhanced clinical effectiveness in patients
-
The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice Cancer Treat. Rev. (IF 11.8) Pub Date : 2023-10-12 Jordi Badia-Ramentol, Francisco Gimeno-Valiente, Elena Duréndez, Carolina Martínez-Ciarpaglini, Jenniffer Linares, Mar Iglesias, Andrés Cervantes, Alexandre Calon, Noelia Tarazona
Adjuvant chemotherapy following surgical intervention remains the primary treatment option for patients with localized colorectal cancer (CRC). However, a significant proportion of patients will have an unfavorable outcome after current forms of chemotherapy. While reflecting the increasing complexity of CRC, the clinical application of molecular biomarkers provides information that can be utilized